To validate these findings at the protein level, we evaluated FOSL1 expression in glial fibrillary acidic protein (GFAP)‐positive tumor cells—used as a GBM marker—within brain tumor tissues from patients clinically categorized as TMZ resistant or TMZ sensitive. Here, GFAP is linked to neoplasm.